References
- Ametzazurra A, Larrea E, Civeira MP, et al. (2008). Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis. Oncogene 27:7296–306
- Anderson NG, Maller JL, Tonks NK, Sturgill TW. (1990). Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343:651–3
- Blesa JMG, Pulido EG, Pulla MP, Candel VA. (2009). Treatment options for metastatic melanoma. A systematic review. Canc Ther 7:188–99
- Breyer-Pfaff U, Wachsmuth H. (2001). Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine. Drug Metab Dispos 29:1343–8
- Chapman PB, Hauschild A, Robert C, et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 364:2507–16
- Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. (2004). Drug--protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16
- Falchook GS, Lewis KD, Infante JR, et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase I dose-escalation trial. Lancet Oncol 13:782–9
- Fremin C, Meloche S. (2010). From basic research to clinical development fo MEK 1/2 inhibitors for cancer therapy. J Hematol Oncol 3:8
- Flaherty KT, Robert C, Hersey P, et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–14
- Gilmartin AG, Bleam MR, Groy A, et al. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17:989–1000
- Gschwind HP, Pfaar U, Waldmeier F, et al. (2005). Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503–12
- Hodi FS, O’Day SJ, McDermott DF, et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–23
- Hop C, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling method to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- ICRP (1992). Radiological protection in biomedical research. ICRP Publication 62. Ann. ICRP 22:3--4
- Infante JR, LaFecher LA, Falchook GS, et al. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13:773–81
- Kamb A, Wee S, Lengauer C. (2007). Why is cancer drug discovery so difficult? Nat Rev Drug Discov 6:115–20
- Lemech C, Infante J, Arkenau H. (2012). The potential for BRAFV600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol 4:61–73
- Madan A, Fisher A, Jim L, et al. (2007). In vitro metabolism of Indiplon and an assessment of its drug interaction potential. Xenobioticia 37:736–52
- McArthur GA. (2012). The coming of age of MEK. Lancet Oncol 13:744–5
- Nicholls AW, Lindon JC, Farrant RD, et al. (1999). Directly-coupled HPLC-NMR spectroscopic studies of metabolism and futile deacetylation of phenacetin in the rat. J Pharm Biomed Anal 20:865–73
- Ray LB, Sturgill TW. (1988). Characterization of insulin-stimulated microtubule-associated protein kinase. Rapid isolation and stabilization of a novel serine/threonine kinase from 3T3-L1 cells. J Biol Chem 263:12721–7
- Roffey S, Obach RS, Gedge JI, Smith D. (2007). What is the objective of the Mass Balance Study? A retrospective analysis of data in animal and human excretion studies employing radiolabelled drugs. Drug Metab Rev 39:17–43
- Tomoda A, Yamaguchi J, Kojima H, et al. (1986). Mechanism of o-aminophenol metabolism in human erythrocytes. FEBS Lett 196:44–8
- Toutain PL, Bousquet-Melou A. (2004). Volumes of distribution. J Vet Pharmacol Therap 27:441–53
- van Hogezand RA, Kennis HM, van Schaik A, et al. (1992). Bacterial acetylation of 5-aminosalicylic acid in fecal suspension cultured under aerobic and anaerobic conditions. Eur J Clin Pharmacol 43:189–92
- Yuan J, Yang D, Zhang J, et al. (2002). Disposition of a specific cyclooxygenase-2, Valdecoxib, in human. Drug Metab Dispos 30:1013–21
- Zandvliet AS, Copalu W, Schellens JHM, et al. (2006). Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metab Dispos 34:1041–6
- Zhao JS, Singh A, Huang XD, Ward OP. (2000). Biotransformation of hydroxyaminobenzene and aminophenol by Pseudomonas putida 2NP8 cells grown in the presence of 3-nitrophenol. Appl Environ Microbiol 66:2336–42